OpenAI now owns Orchestra Bio, a startup whose software keeps drug programs moving across biopharma teams. The team and product fold into Rosalind, the company’s life sciences unit, according to Unite.AI.
The pitch is scheduling and coordination rather than chemistry. Bringing a molecule from a target to approval routinely eats 10 to 15 years, and much of that time disappears into handoffs between internal departments and outside partners working on systems that do not talk to each other. Orchestra’s agents monitor studies and campaigns, trace how one delay ripples into other work, gather the relevant documents and lay out the response options for the scientists who decide.
Rosalind supplies the scientific reasoning. GPT-Rosalind is trained for biology and chemistry questions, while Rosalind Workbench connects those models to tools and data so researchers can plan experiments. Workbench is still in research preview, with a general Explore mode and a deeper Research mode behind an application.
OpenAI published per-token benchmark gains of 53.7% on Genebench, 18.0% on Medchem Bench and 19.6% on Labworkbench, though those figures measure efficiency rather than clinical value.
The company is also building out its pharma relationships. It points to partnerships with Novo Nordisk and Moderna, a sponsored-access tier for academic labs, an enterprise route with governance review, and a biodefense program for public health teams.
Orchestra’s founders said the move lets them pursue their original mission at larger scale.
